FDA approves tavapadon, a D1/D5 dopamine agonist, for Parkinson's disease

The Food and Drug Administration has approved tavapadon, an oral drug for Parkinson's disease that works on a different set of dopamine receptors than the agonists already in wide use. The agency recorded the approval in its Drugs@FDA database on 25 September 2026 under new drug application 220415, held by AbbVie, and classified it as a Type 1 new molecular entity [s1]. The product, brand name Juvmo, is a tablet supplied in five strengths — 0.25, 1, 5, 10 and 15 mg — taken once daily [s1].

Tavapadon is a selective partial agonist at the D1 and D5 dopamine receptors [s2]. That matters because the older dopamine agonists used in Parkinson's — such as pramipexole and ropinirole — act preferentially on the D2 and D3 receptors, a route linked to adverse effects including impulse-control problems and daytime sleepiness. The hope with a D1/D5-selective drug is to drive the motor benefit while sidestepping some of that burden. Whether it delivers on that promise in practice is the open question; no trial has tested it head-to-head against a D2/D3 agonist.

What the pivotal programme tested

The approval rests on a three-trial phase 3 programme, all double-blind and placebo-controlled, covering both ends of the disease.

TEMPO-1 and TEMPO-2 studied people with early Parkinson's — under three years since diagnosis, treatment-naive or with less than three months of prior dopaminergic treatment — using tavapadon on its own [s3][s4]. TEMPO-3 studied a later stage: adults already on stable oral levodopa (at least 400 mg a day) who had developed motor fluctuations, with tavapadon added on top [s2]. Across the three trials the drug was tested at sites in a dozen or more countries [s2][s3][s4].

What the trials found

In TEMPO-1, 529 patients with early disease were randomised to tavapadon 5 mg, tavapadon 15 mg or placebo [s3]. The primary measure was the change at week 26 in the combined Parts II and III score of the MDS-UPDRS, a scale of daily function and motor signs on which a larger fall means more improvement. The 5 mg dose produced a 9.7-point decrease versus a 1.8-point increase on placebo (treatment difference −11.5 points; 95% CI −13.8 to −9.2; P<.001), and the 15 mg dose a 10.2-point decrease (difference −12.1 points; 95% CI −14.4 to −9.8; P<.001) [s3]. TEMPO-2, the flexible-dose early-disease trial, randomised 304 patients and found a least-squares mean decrease of 10.3 points on the same scale versus 1.2 on placebo [s4].

TEMPO-3 tested the add-on use. Of 507 patients on levodopa, 252 received tavapadon and 255 placebo [s2]. Daily "good on-time" — hours of good mobility without troublesome dyskinesia — rose by 1.70 hours on the drug against 0.60 hours on placebo, a difference of 1.10 hours (95% CI 0.60 to 1.70; P<.001) [s2]. Daily off-time fell by 1.88 hours versus 0.93 hours on placebo (difference −0.94 hours; 95% CI −1.48 to −0.41; P<.001) [s2].

Safety and tolerability

More patients had adverse events on tavapadon than on placebo — in TEMPO-3, 71.7% versus 55.1% — but most were nonserious and mild to moderate [s2]. The common ones were nausea, dizziness, headache and dyskinesia; in TEMPO-3 nausea affected 14.3%, dyskinesia 10.0% and dizziness 7.6% [s2]. In the early-disease trials nausea was more frequent still, reported by about a quarter of treated patients in TEMPO-1 [s3]. Tolerability was not trivial: in TEMPO-2, 38% of the tavapadon group discontinued the trial compared with 15% on placebo, most often because of adverse events [s4].

How to read it

The efficacy signal is consistent — tavapadon separated from placebo in all three trials, in both early and fluctuating disease [s2][s3][s4]. The honest caveats are two. First, the trials ran about six months, so they speak to the first half-year of treatment, not the years over which Parkinson's is actually managed [s2]. Second, the drug's central selling point — a cleaner side-effect profile than D2/D3 agonists — has not been tested directly against those drugs, and the dropout seen in TEMPO-2 is a reminder that "better tolerated" is a claim still to be earned in use [s4].

What to watch

The near-term questions are practical: exactly which patients the prescribing information covers, how tavapadon is positioned against levodopa and the older agonists, and whether the impulse-control and sleep problems that dog D2/D3 drugs prove genuinely less common here. Longer follow-up and real-world data will decide that.

This article describes research and regulatory news and is not medical advice. Anyone with Parkinson's considering a change in treatment should discuss it with their neurologist; sudden stops or swaps of dopaminergic drugs can be dangerous, and new or worsening impulse-control urges, severe daytime sleepiness, hallucinations or fainting are red flags that warrant prompt medical attention.

Sources

• Drugs@FDA: Juvmo (tavapadon), NDA 220415 — approval record — U.S. Food and Drug Administration, approved 25 September 2026
• Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial — JAMA Neurology, 2026
• Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical Trial (TEMPO-1) — JAMA Neurology, 2026
• Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial — The Lancet Neurology, 2026